solo per uso di ricerca
N. Cat.S8059
| Target correlati | Bcl-2 Caspase PD-1/PD-L1 Ferroptosis p53 Apoptosis related Synthetic Lethality STAT TNF-alpha Ras |
|---|---|
| Altro MDM2/MDMX Inibitori | Nutlin-3 RG-7112 Brigimadlin Idasanutlin (RG7388) SAR405838 NSC 207895 NVP-CGM097 Siremadlin (HDM201) Nutlin-3b YH239-EE |
| Linee cellulari | Tipo di saggio | Concentrazione | Tempo di incubazione | Formulazione | Descrizione dell'attività | PMID |
|---|---|---|---|---|---|---|
| MV-4-11 | Growth Inhibition Assay | IC50=0.61237 μM | SANGER | |||
| H4 | Growth Inhibition Assay | IC50=0.6628 μM | SANGER | |||
| PA-1 | Growth Inhibition Assay | IC50=0.87096 μM | SANGER | |||
| NKM-1 | Growth Inhibition Assay | IC50=1.04931 μM | SANGER | |||
| NEC8 | Growth Inhibition Assay | IC50=1.21572 μM | SANGER | |||
| EoL-1-cell | Growth Inhibition Assay | IC50=1.26701 μM | SANGER | |||
| K5 | Growth Inhibition Assay | IC50=1.42072 μM | SANGER | |||
| QIMR-WIL | Growth Inhibition Assay | IC50=1.60854 μM | SANGER | |||
| MOLT-16 | Growth Inhibition Assay | IC50=1.78604 μM | SANGER | |||
| CHP-212 | Growth Inhibition Assay | IC50=1.81369 μM | SANGER | |||
| CTB-1 | Growth Inhibition Assay | IC50=2.02246 μM | SANGER | |||
| MOLT-4 | Growth Inhibition Assay | IC50=2.32853 μM | SANGER | |||
| A101D | Growth Inhibition Assay | IC50=2.3501 μM | SANGER | |||
| DOHH-2 | Growth Inhibition Assay | IC50=2.42279 μM | SANGER | |||
| ES4 | Growth Inhibition Assay | IC50=2.43155 μM | SANGER | |||
| SW780 | Growth Inhibition Assay | IC50=2.50883 μM | SANGER | |||
| VA-ES-BJ | Growth Inhibition Assay | IC50=2.5411 μM | SANGER | |||
| RPMI-8866 | Growth Inhibition Assay | IC50=2.56214 μM | SANGER | |||
| ML-2 | Growth Inhibition Assay | IC50=2.56576 μM | SANGER | |||
| MSTO-211H | Growth Inhibition Assay | IC50=2.57451 μM | SANGER | |||
| JVM-3 | Growth Inhibition Assay | IC50=2.59324 μM | SANGER | |||
| A3-KAW | Growth Inhibition Assay | IC50=2.61818 μM | SANGER | |||
| DK-MG | Growth Inhibition Assay | IC50=2.62471 μM | SANGER | |||
| LNCaP-Clone-FGC | Growth Inhibition Assay | IC50=2.64318 μM | SANGER | |||
| HT-144 | Growth Inhibition Assay | IC50=2.64577 μM | SANGER | |||
| NB69 | Growth Inhibition Assay | IC50=2.65334 μM | SANGER | |||
| A172 | Growth Inhibition Assay | IC50=2.67588 μM | SANGER | |||
| RS4-11 | Growth Inhibition Assay | IC50=2.72407 μM | SANGER | |||
| DU-4475 | Growth Inhibition Assay | IC50=2.79502 μM | SANGER | |||
| SJSA-1 | Growth Inhibition Assay | IC50=2.82556 μM | SANGER | |||
| BV-173 | Growth Inhibition Assay | IC50=2.84439 μM | SANGER | |||
| U-2-OS | Growth Inhibition Assay | IC50=2.9107 μM | SANGER | |||
| CHP-134 | Growth Inhibition Assay | IC50=2.93882 μM | SANGER | |||
| D-502MG | Growth Inhibition Assay | IC50=2.97154 μM | SANGER | |||
| KS-1 | Growth Inhibition Assay | IC50=3.01623 μM | SANGER | |||
| A204 | Growth Inhibition Assay | IC50=3.05588 μM | SANGER | |||
| KGN | Growth Inhibition Assay | IC50=3.08496 μM | SANGER | |||
| NCI-H292 | Growth Inhibition Assay | IC50=3.12028 μM | SANGER | |||
| CAKI-1 | Growth Inhibition Assay | IC50=3.12694 μM | SANGER | |||
| C2BBe1 | Growth Inhibition Assay | IC50=3.17026 μM | SANGER | |||
| NB10 | Growth Inhibition Assay | IC50=3.20966 μM | SANGER | |||
| MHH-NB-11 | Growth Inhibition Assay | IC50=3.26827 μM | SANGER | |||
| NCI-SNU-1 | Growth Inhibition Assay | IC50=3.27843 μM | SANGER | |||
| HCT-116 | Growth Inhibition Assay | IC50=3.30335 μM | SANGER | |||
| G-401 | Growth Inhibition Assay | IC50=3.36322 μM | SANGER | |||
| MN-60 | Growth Inhibition Assay | IC50=3.44092 μM | SANGER | |||
| SW982 | Growth Inhibition Assay | IC50=3.50848 μM | SANGER | |||
| RKO | Growth Inhibition Assay | IC50=3.53936 μM | SANGER | |||
| D-283MED | Growth Inhibition Assay | IC50=3.57986 μM | SANGER | |||
| LB996-RCC | Growth Inhibition Assay | IC50=3.62558 μM | SANGER | |||
| A549 | Growth Inhibition Assay | IC50=3.63552 μM | SANGER | |||
| LB2241-RCC | Growth Inhibition Assay | IC50=3.65708 μM | SANGER | |||
| SK-HEP-1 | Growth Inhibition Assay | IC50=3.74297 μM | SANGER | |||
| G-402 | Growth Inhibition Assay | IC50=3.80832 μM | SANGER | |||
| GOTO | Growth Inhibition Assay | IC50=3.84333 μM | SANGER | |||
| LOXIMVI | Growth Inhibition Assay | IC50=3.85675 μM | SANGER | |||
| NH-12 | Growth Inhibition Assay | IC50=4.01959 μM | SANGER | |||
| CTV-1 | Growth Inhibition Assay | IC50=4.07973 μM | SANGER | |||
| CP50-MEL-B | Growth Inhibition Assay | IC50=4.24392 μM | SANGER | |||
| RH-18 | Growth Inhibition Assay | IC50=4.27706 μM | SANGER | |||
| NB17 | Growth Inhibition Assay | IC50=4.31768 μM | SANGER | |||
| A375 | Growth Inhibition Assay | IC50=4.33524 μM | SANGER | |||
| IST-MES1 | Growth Inhibition Assay | IC50=4.41411 μM | SANGER | |||
| MZ2-MEL | Growth Inhibition Assay | IC50=4.50155 μM | SANGER | |||
| CAL-54 | Growth Inhibition Assay | IC50=4.53019 μM | SANGER | |||
| NCI-H28 | Growth Inhibition Assay | IC50=4.62717 μM | SANGER | |||
| D-247MG | Growth Inhibition Assay | IC50=4.75072 μM | SANGER | |||
| NCI-H460 | Growth Inhibition Assay | IC50=4.91127 μM | SANGER | |||
| MCF7 | Growth Inhibition Assay | IC50=5.44244 μM | SANGER | |||
| 697 | Growth Inhibition Assay | IC50=5.4455 μM | SANGER | |||
| ONS-76 | Growth Inhibition Assay | IC50=5.57009 μM | SANGER | |||
| C32 | Growth Inhibition Assay | IC50=5.60029 μM | SANGER | |||
| OS-RC-2 | Growth Inhibition Assay | IC50=5.73887 μM | SANGER | |||
| MEL-HO | Growth Inhibition Assay | IC50=5.85667 μM | SANGER | |||
| LoVo | Growth Inhibition Assay | IC50=6.01624 μM | SANGER | |||
| AGS | Growth Inhibition Assay | IC50=6.14828 μM | SANGER | |||
| GI-ME-N | Growth Inhibition Assay | IC50=6.22421 μM | SANGER | |||
| H-EMC-SS | Growth Inhibition Assay | IC50=6.386 μM | SANGER | |||
| RVH-421 | Growth Inhibition Assay | IC50=6.42428 μM | SANGER | |||
| SW954 | Growth Inhibition Assay | IC50=6.55572 μM | SANGER | |||
| NB5 | Growth Inhibition Assay | IC50=6.56183 μM | SANGER | |||
| NCI-H2122 | Growth Inhibition Assay | IC50=6.58793 μM | SANGER | |||
| AM-38 | Growth Inhibition Assay | IC50=6.75639 μM | SANGER | |||
| KNS-81-FD | Growth Inhibition Assay | IC50=6.76494 μM | SANGER | |||
| LS-513 | Growth Inhibition Assay | IC50=6.79026 μM | SANGER | |||
| A427 | Growth Inhibition Assay | IC50=6.87829 μM | SANGER | |||
| WM-115 | Growth Inhibition Assay | IC50=6.9323 μM | SANGER | |||
| COLO-829 | Growth Inhibition Assay | IC50=7.24188 μM | SANGER | |||
| NCI-H1650 | Growth Inhibition Assay | IC50=7.39228 μM | SANGER | |||
| NCI-H358 | Growth Inhibition Assay | IC50=7.44879 μM | SANGER | |||
| HT-1080 | Growth Inhibition Assay | IC50=7.48254 μM | SANGER | |||
| HCC2218 | Growth Inhibition Assay | IC50=7.6297 μM | SANGER | |||
| NCI-H661 | Growth Inhibition Assay | IC50=7.87069 μM | SANGER | |||
| KM-H2 | Growth Inhibition Assay | IC50=7.88694 μM | SANGER | |||
| RPMI-2650 | Growth Inhibition Assay | IC50=7.94414 μM | SANGER | |||
| NCI-H226 | Growth Inhibition Assay | IC50=8.21122 μM | SANGER | |||
| MKN45 | Growth Inhibition Assay | IC50=8.26602 μM | SANGER | |||
| D-392MG | Growth Inhibition Assay | IC50=8.52722 μM | SANGER | |||
| RCC10RGB | Growth Inhibition Assay | IC50=8.86695 μM | SANGER | |||
| CAL-51 | Growth Inhibition Assay | IC50=9.10251 μM | SANGER | |||
| COLO-678 | Growth Inhibition Assay | IC50=9.32811 μM | SANGER | |||
| SK-MEL-24 | Growth Inhibition Assay | IC50=9.55856 μM | SANGER | |||
| SK-MEL-30 | Growth Inhibition Assay | IC50=9.94476 μM | SANGER | |||
| MMAC-SF | Growth Inhibition Assay | IC50=10.3961 μM | SANGER | |||
| NTERA-S-cl-D1 | Growth Inhibition Assay | IC50=10.6508 μM | SANGER | |||
| NB12 | Growth Inhibition Assay | IC50=11.503 μM | SANGER | |||
| UACC-257 | Growth Inhibition Assay | IC50=11.8695 μM | SANGER | |||
| LAN-6 | Growth Inhibition Assay | IC50=11.9928 μM | SANGER | |||
| SW1573 | Growth Inhibition Assay | IC50=12.3086 μM | SANGER | |||
| NMC-G1 | Growth Inhibition Assay | IC50=12.4175 μM | SANGER | |||
| SHP-77 | Growth Inhibition Assay | IC50=12.5574 μM | SANGER | |||
| IGROV-1 | Growth Inhibition Assay | IC50=12.6573 μM | SANGER | |||
| 22RV1 | Growth Inhibition Assay | IC50=12.8059 μM | SANGER | |||
| SK-MEL-3 | Growth Inhibition Assay | IC50=13.3973 μM | SANGER | |||
| NCI-H1563 | Growth Inhibition Assay | IC50=13.4202 μM | SANGER | |||
| IGR-1 | Growth Inhibition Assay | IC50=14.0347 μM | SANGER | |||
| EW-3 | Growth Inhibition Assay | IC50=14.1639 μM | SANGER | |||
| JEG-3 | Growth Inhibition Assay | IC50=14.4953 μM | SANGER | |||
| ES3 | Growth Inhibition Assay | IC50=14.6562 μM | SANGER | |||
| MDA-MB-175-VII | Growth Inhibition Assay | IC50=14.7111 μM | SANGER | |||
| P30-OHK | Growth Inhibition Assay | IC50=15.0496 μM | SANGER | |||
| GP5d | Growth Inhibition Assay | IC50=15.1466 μM | SANGER | |||
| HMV-II | Growth Inhibition Assay | IC50=15.3333 μM | SANGER | |||
| COLO-679 | Growth Inhibition Assay | IC50=15.501 μM | SANGER | |||
| JAR | Growth Inhibition Assay | IC50=15.7205 μM | SANGER | |||
| NCI-H1666 | Growth Inhibition Assay | IC50=15.9399 μM | SANGER | |||
| SW48 | Growth Inhibition Assay | IC50=15.9516 μM | SANGER | |||
| NCI-H720 | Growth Inhibition Assay | IC50=15.9989 μM | SANGER | |||
| HT-1197 | Growth Inhibition Assay | IC50=16.0352 μM | SANGER | |||
| HL-60 | Growth Inhibition Assay | IC50=16.0384 μM | SANGER | |||
| BEN | Growth Inhibition Assay | IC50=16.5638 μM | SANGER | |||
| HAL-01 | Growth Inhibition Assay | IC50=16.8909 μM | SANGER | |||
| SW900 | Growth Inhibition Assay | IC50=16.9132 μM | SANGER | |||
| SBC-1 | Growth Inhibition Assay | IC50=17.5429 μM | SANGER | |||
| SH-4 | Growth Inhibition Assay | IC50=17.5841 μM | SANGER | |||
| UACC-62 | Growth Inhibition Assay | IC50=17.7637 μM | SANGER | |||
| BHT-101 | Growth Inhibition Assay | IC50=19.8705 μM | SANGER | |||
| DB | Growth Inhibition Assay | IC50=21.5649 μM | SANGER | |||
| SK-MEL-1 | Growth Inhibition Assay | IC50=21.5872 μM | SANGER | |||
| NCI-H747 | Growth Inhibition Assay | IC50=22.7379 μM | SANGER | |||
| SK-LU-1 | Growth Inhibition Assay | IC50=23.3524 μM | SANGER | |||
| KG-1 | Growth Inhibition Assay | IC50=23.4946 μM | SANGER | |||
| LXF-289 | Growth Inhibition Assay | IC50=23.714 μM | SANGER | |||
| HCC1954 | Growth Inhibition Assay | IC50=24.8844 μM | SANGER | |||
| Ramos-2G6-4C10 | Growth Inhibition Assay | IC50=26.4981 μM | SANGER | |||
| DBTRG-05MG | Growth Inhibition Assay | IC50=26.6488 μM | SANGER | |||
| NCI-H2052 | Growth Inhibition Assay | IC50=27.5684 μM | SANGER | |||
| RMG-I | Growth Inhibition Assay | IC50=29.4139 μM | SANGER | |||
| H9 | Growth Inhibition Assay | IC50=31.3008 μM | SANGER | |||
| GR-ST | Growth Inhibition Assay | IC50=32.4453 μM | SANGER | |||
| Mo-T | Growth Inhibition Assay | IC50=32.5046 μM | SANGER | |||
| SW1088 | Growth Inhibition Assay | IC50=32.9801 μM | SANGER | |||
| LB2518-MEL | Growth Inhibition Assay | IC50=33.0797 μM | SANGER | |||
| NCI-H82 | Growth Inhibition Assay | IC50=33.1661 μM | SANGER | |||
| LAMA-84 | Growth Inhibition Assay | IC50=34.6073 μM | SANGER | |||
| KYSE-450 | Growth Inhibition Assay | IC50=34.6776 μM | SANGER | |||
| LU-99A | Growth Inhibition Assay | IC50=35.0007 μM | SANGER | |||
| BE-13 | Growth Inhibition Assay | IC50=35.6545 μM | SANGER | |||
| GAK | Growth Inhibition Assay | IC50=35.695 μM | SANGER | |||
| NCI-H1573 | Growth Inhibition Assay | IC50=35.8818 μM | SANGER | |||
| AsPC-1 | Growth Inhibition Assay | IC50=36.1527 μM | SANGER | |||
| HDLM-2 | Growth Inhibition Assay | IC50=36.316 μM | SANGER | |||
| NCI-H441 | Growth Inhibition Assay | IC50=37.0691 μM | SANGER | |||
| CAL-27 | Growth Inhibition Assay | IC50=37.7231 μM | SANGER | |||
| OVCAR-3 | Growth Inhibition Assay | IC50=39.3181 μM | SANGER | |||
| RPMI-8226 | Growth Inhibition Assay | IC50=39.598 μM | SANGER | |||
| EFO-21 | Growth Inhibition Assay | IC50=40.5814 μM | SANGER | |||
| SNU-C2B | Growth Inhibition Assay | IC50=41.5084 μM | SANGER | |||
| VM-CUB-1 | Growth Inhibition Assay | IC50=43.8037 μM | SANGER | |||
| NCI-H2087 | Growth Inhibition Assay | IC50=45.0233 μM | SANGER | |||
| EW-16 | Growth Inhibition Assay | IC50=46.3137 μM | SANGER | |||
| SK-N-AS | Growth Inhibition Assay | IC50=46.7167 μM | SANGER | |||
| COR-L105 | Growth Inhibition Assay | IC50=46.8857 μM | SANGER | |||
| DEL | Growth Inhibition Assay | IC50=48.0429 μM | SANGER | |||
| JVM-2 | Growth Inhibition Assay | IC50=48.0558 μM | SANGER | |||
| KARPAS-45 | Growth Inhibition Assay | IC50=49.4538 μM | SANGER | |||
| BL21 (DE3) | Function assay | Binding affinity to human recombinant Mdm2 T101W mutant expressed in Escherichia coli BL21 (DE3) cells by antagonist induced dissociation assay, Kd = 0.5 μM. | 18680271 | |||
| BL21 (DE3) | Function assay | Binding affinity to human recombinant Mdm2 K98W mutant expressed in Escherichia coli BL21 (DE3) cells by antagonist induced dissociation assay, Kd = 0.5 μM. | 18680271 | |||
| BL21 (DE3) | Function assay | Binding affinity to human recombinant Mdm2 F55W mutant expressed in Escherichia coli BL21 (DE3) cells by NMR ligand-protein binary titration, Kd = 0.5 μM. | 18680271 | |||
| SJSA1 | Antiproliferative assay | 3 days | Antiproliferative activity against human SJSA1 cells after 3 days by EdU incorporation assay in presence of 10% human serum, IC50 = 0.7 μM. | 22524527 | ||
| HCT116 | Function assay | 24 hrs | Induction of p53-Ser15 phosphorylation in human HCT116 cells after 24 hrs, IC50 = 1 μM. | 19856920 | ||
| BL21 (DE3) | Function assay | Binding affinity to human recombinant Mdm2 T101W mutant expressed in Escherichia coli BL21 (DE3) cells by NMR ligand-protein binary titration, Kd = 1 μM. | 18680271 | |||
| BL21 (DE3) | Function assay | Binding affinity to human recombinant Mdm2 K98W mutant expressed in Escherichia coli BL21 (DE3) cells by NMR ligand-protein binary titration, Kd = 1 μM. | 18680271 | |||
| SJSA1 | Cytotoxicity assay | Cytotoxicity against human SJSA1 cells, IC50 = 1 μM. | 25396320 | |||
| RKO | Cytotoxicity assay | Cytotoxicity against human RKO cells, IC50 = 1 μM. | 25396320 | |||
| HCT116 | Cytotoxicity assay | Cytotoxicity against human HCT116 cells, IC50 = 1 μM. | 25396320 | |||
| SJSA1 | Growth inhibition assay | Growth inhibition of human SJSA1 cells expressing MDM2 by SRB assay, GI50 = 1.3 μM. | 21875801 | |||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells expressing wild type p53 incubated for 72 hrs by MTS assay, IC50 = 1.3 μM. | 30221935 | ||
| HCT116 | Function assay | 8 hrs | Induction of p53 in human HCT116 cells coexpressing pp53TA-luc assessed as inhibition of cell proliferation after 8 hrs by firefly/renilla luciferase reporter assay, IC50 = 1.39 μM. | 19856920 | ||
| HGF | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HGF cells after 24 hrs by MTT assay, IC50 = 1.4 μM. | 23802716 | ||
| SJSA1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SJSA1 cells expressing wild type p53 incubated for 72 hrs by MTS assay, IC50 = 1.44 μM. | 30221935 | ||
| SJSA1 | Cytotoxicity assay | 5 days | Cytotoxicity against human SJSA1 cells expressing wild type p53 assessed as cell viability after 5 days by MTT assay, IC50 = 1.5 μM. | 24900694 | ||
| RKO | Cytotoxicity assay | 5 days | Cytotoxicity against human RKO cells expressing wild type p53 assessed as cell viability after 5 days by MTT assay, IC50 = 1.5 μM. | 24900694 | ||
| HCT116 | Cytotoxicity assay | 5 days | Cytotoxicity against human HCT116 cells expressing wild type p53 assessed as cell viability after 5 days by MTT assay, IC50 = 1.5 μM. | 24900694 | ||
| A2780 | Growth inhibition assay | Growth inhibition of human A2780 cells expressing MDM2 by SRB assay, GI50 = 1.6 μM. | 21875801 | |||
| HCT116 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HCT116 cells after 72 hrs by CellTiterGlo luciferase-based assay, IC50 = 1.6 μM. | 24139845 | ||
| SJSA1 | Antiproliferative assay | Antiproliferative activity against human SJSA1 cells, IC50 = 1.9 μM. | 24656661 | |||
| SJSA1 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SJSA1 cells expressing wild type p53 after 72 hrs by CellTitre-Glo assay, IC50 = 1.9 μM. | 26985323 | ||
| HCT116 | Growth inhibition assay | Growth inhibition of human HCT116 cells expressing MDM2 by SRB assay, GI50 = 2.1 μM. | 21875801 | |||
| NGP | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NGP cells after 72 hrs by sulforhodamine B assay, GI50 = 2.1 μM. | 21314128 | ||
| LS | Cytotoxicity assay | 72 hrs | Cytotoxicity against human LS cells after 72 hrs by sulforhodamine B assay, GI50 = 2.3 μM. | 21314128 | ||
| SJSA1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SJSA1 cells after 72 hrs by sulforhodamine B assay, GI50 = 2.6 μM. | 21314128 | ||
| MCF7 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay, IC50 = 2.9 μM. | 23802716 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity in p53 (+/+) human HCT116 cells incubated for 72 hrs by MTS assay, IC50 = 4 μM. | 28987608 | ||
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells expressing wild type p53 assessed as growth inhibition after 72 hrs by SRB assay, IC50 = 4.62 μM. | 23601819 | ||
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells expressing wild type p53 after 72 hrs by SRB assay, IC50 = 4.62 μM. | 23611770 | ||
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 5.01 μM. | 27101893 | ||
| HepG2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay, IC50 = 5.1 μM. | 25479770 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells expressing wild type p53 assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 5.21 μM. | 27101893 | ||
| UKF-NB-3 | Cytotoxicity assay | 96 hrs | Cytotoxicity against doxorubicin-resistant human UKF-NB-3 cells after 96 hrs by MTT assay, IC50 = 5.56 μM. | 20947617 | ||
| SJSA1 | Function assay | 7 hrs | Activity at p53 in human SJSA1 cells assessed as induction of p21 mRNA expression after 7 hrs by qRT-PCR analysis in presence of 10% human serum, IC50 = 7.1 μM. | 22524527 | ||
| HCT116 | Growth inhibition assay | 48 hrs | Growth inhibition of human HCT116 cells harboring p53+/+ after 48 hrs by Hoechst 33258 staining based fluorescence assay, GI50 = 8 μM. | 29089230 | ||
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay, IC50 = 8.5 μM. | 30045621 | ||
| HCT116 | Antiproliferative assay | 24 hrs | Antiproliferative activity against human HCT116 p53+/+ cells assessed as growth inhibition after 24 hrs by EdU/Hoechst 33342 staining-based fluorescence analysis, GI50 = 9 μM. | 29691156 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay, IC50 = 9.07 μM. | 30045621 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay, IC50 = 9.58 μM. | 30045621 | ||
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay, IC50 = 10.2 μM. | 23802716 | ||
| NCI-H1299 | Antiproliferative assay | 72 hrs | Antiproliferative activity against p53 -/- human NCI-H1299 cells incubated for 72 hrs by MTS assay, IC50 = 10.4 μM. | 30221935 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50 = 11.6 μM. | 25618595 | ||
| Saos2 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human p53-deficient Saos2 cells after 72 hrs by MTT assay, IC50 = 12.1 μM. | 22940704 | ||
| HCT116 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human p53 expressing HCT116 cells after 72 hrs by sulforhodamine B assay, GI50 = 13 μM. | 21314128 | ||
| U2OS | Antiproliferative assay | 72 hrs | Antiproliferative activity against human U2OS cells expressing wild type p53 after 72 hrs by MTT assay, IC50 = 14.31 μM. | 23046248 | ||
| H1299 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human H1299 cells after 72 hrs by CellTiterGlo luciferase-based assay, IC50 = 14.7 μM. | 24139845 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells expressing wild type p53 after 72 hrs by MTT assay, IC50 = 15 μM. | 22940704 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells expressing wild type p53 after 72 hrs by MTT assay, IC50 = 15.12 μM. | 23046248 | ||
| U937 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human U937 cells after 24 hrs by MTT assay, IC50 = 15.6 μM. | 23802716 | ||
| Saos2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human Saos2 cells after 72 hrs by sulforhodamine B assay, GI50 = 18 μM. | 21314128 | ||
| U2OS | Antiproliferative assay | 72 hrs | Antiproliferative activity against human U2OS cells expressing wild type p53 after 72 hrs by MTT assay, IC50 = 19.6 μM. | 22940704 | ||
| NCI-H1299 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay, IC50 = 19.76 μM. | 30045621 | ||
| PC3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human p53-null PC3 cells assessed as growth inhibition after 72 hrs by SRB assay, IC50 = 20.04 μM. | 23601819 | ||
| PC3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human p53 deficient PC3 cells after 72 hrs by SRB assay, IC50 = 20.04 μM. | 23611770 | ||
| A2780/CP70 | Growth inhibition assay | Growth inhibition of human A2780/CP70 cells expressing isogenically paired p53 mutant by SRB assay, GI50 = 20.4 μM. | 21875801 | |||
| NCI-H1299 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human p53-deficient NCI-H1299 cells after 72 hrs by MTT assay, IC50 = 20.4 μM. | 22940704 | ||
| NCI-H1299 | Antiproliferative assay | 72 hrs | Antiproliferative activity against p53 deficient human NCI-H1299 cells after 72 hrs by MTT assay, IC50 = 20.48 μM. | 23046248 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human p53-null HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 21.5 μM. | 27101893 | ||
| SJSA1 | Cytotoxicity assay | 24 hrs | Cytotoxicity in human SJSA1 cells over expressing human DM2 after 24 hrs by CellTiter-Glo assay, EC50 = 22.8 μM. | 29150077 | ||
| C643 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human C643 cells after 24 hrs by MTT assay, IC50 = 23 μM. | 23802716 | ||
| MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 23.5 μM. | 25618595 | ||
| U2OS | Antitumor assay | 72 hrs | Antitumor activity against human U2OS cells expressing wild type p53 after 72 hrs by MTT assay, IC50 = 24.61 μM. | 21996465 | ||
| HCT116 | Growth inhibition assay | Growth inhibition of p53 deficient human HCT116 cells expressing MDM2 by SRB assay, GI50 = 25.6 μM. | 21875801 | |||
| HCT116 | Growth inhibition assay | 48 hrs | Growth inhibition of human p53 knockdown HCT116 cells after 48 hrs by Hoechst 33258 staining based fluorescence assay, GI50 = 27 μM. | 29089230 | ||
| Calu | Cytotoxicity assay | 24 hrs | Cytotoxicity against human Calu cells after 24 hrs by MTT assay, IC50 = 27.2 μM. | 23802716 | ||
| HCT116 | Antiproliferative assay | 24 hrs | Antiproliferative activity against human HCT116 p53-/- cells assessed as growth inhibition after 24 hrs by EdU/Hoechst 33342 staining-based fluorescence analysis, GI50 = 29 μM. | 29691156 | ||
| MDA-MB-435S | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MDA-MB-435S cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 29.6 μM. | 27101893 | ||
| PC3 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human PC3 cells after 24 hrs by MTT assay, IC50 = 30.3 μM. | 23802716 | ||
| Saos2 | Antiproliferative assay | 72 hrs | Antiproliferative activity against p53 deficient human Saos2 cells after 72 hrs by MTT assay, IC50 = 31.62 μM. | 23046248 | ||
| HCT116 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HCT116 cells expressing wild type p53 after 48 hrs by MTT assay, GI50 = 32.11 μM. | 24852275 | ||
| HCT116 | Cytotoxicity assay | 72 hrs | Cytotoxicity against p53 deficient human HCT116 cells after 72 hrs by sulforhodamine B assay, GI50 = 34 μM. | 21314128 | ||
| HCT116 | Antiproliferative assay | 24 hrs | Antiproliferative activity against human HCT116 cells expressing p53 after 24 hrs by MTS assay, GI50 = 39.65 μM. | 24268795 | ||
| A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells after 48 hrs by MTT assay, GI50 = 47.59 μM. | 24852275 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity in p53 (-/-) human HCT116 cells incubated for 72 hrs by MTS assay, IC50 = 47.8 μM. | 28987608 | ||
| MCF7 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay, GI50 = 48.74 μM. | 24852275 | ||
| SJSA1 | Function assay | 10 uM | Inhibition of MDM2-p53 interaction in human SJSA1 cells assessed as p53 activation at 10 uM by Western blot | 19928922 | ||
| MCF7 | Cell cycle assay | 4 uM | 14 days | Induction of cell cycle arrest in human MCF7 cells transfected with p53-targeting iRNA-based shRNA at 4 uM after 14 days by BrdU incorporation assay | 16474381 | |
| MCF7 | Cell cycle assay | 4 uM | 14 days | Induction of cell cycle arrest in human MCF7 cells transfected hnRNPK-targeting iRNA-based shRNA at 4 uM after 14 days by BrdU incorporation assay | 16474381 | |
| MCF7 | Antiproliferative assay | 4 uM | 14 days | Antiproliferative activity against human MCF7 cells at 4 uM after 14 days by coomassie staining | 16474381 | |
| MCF7 | Antiproliferative assay | 4 uM | 14 days | Antiproliferative activity against human MCF7 cells assessed as appearance of flattened phenotype at 4 uM after 14 days by coomassie staining | 16474381 | |
| MCF7 | Function assay | Induction of p53 expression in human MCF7 cells transfected with 53BP1-targeting iRNA-based shRNA by Western blot analysis | 16474381 | |||
| MCF7 | Function assay | Induction of p53 expression in human MCF7 cells by Western blot analysis | 16474381 | |||
| MCF7 | Function assay | 18 hrs | Induction of p53 accumulation in human MCF7 cells after 18 hrs by Western blot analysis in presence of 2.5 mM caffeine | 16474381 | ||
| BJ | Function assay | 3 uM | Induction of p21CIP1 expression in irradiated human BJ cells at 3 uM by Western blot analysis | 16474381 | ||
| MCF7 | Cell cycle assay | 4 uM | 14 days | Induction of cell cycle arrest in human MCF7 cells transfected with 53BP1-targeting iRNA-based shRNA at 4 uM after 14 days by BrdU incorporation assay | 16474381 | |
| BJ | Function assay | 3 uM | Induction of p21 expression in irradiated human BJ cells at 3 uM by Western blot analysis | 16474381 | ||
| SNJSA1 | Function assay | 1 to 10 uM | 6 hrs | Inhibition of Mdm2 -p53 protein interaction in human SNJSA1 cells assessed as induction of p21 protein at 1 to 10 uM after 6 hrs by Western blot analysis | 21314128 | |
| SNJSA1 | Function assay | 1 to 10 uM | 6 hrs | Inhibition of Mdm2 -p53 protein interaction in human SNJSA1 cells assessed as induction of p53 protein at 1 to 10 uM after 6 hrs by Western blot analysis | 21314128 | |
| SNJSA1 | Function assay | 1 to 10 uM | 6 hrs | Inhibition of Mdm2 -p53 protein interaction in human SNJSA1 cells assessed as induction of MDM2 protein at 1 to 10 uM after 6 hrs by Western blot analysis | 21314128 | |
| MCF7 | Function assay | 24 hrs | Upregulation of p53 in human MCF7 cells after 24 hrs by Western blot analysis | 27010502 | ||
| MCF7 | Function assay | 24 hrs | Upregulation of Mdm2 in human MCF7 cells after 24 hrs by Western blot analysis | 27010502 | ||
| MCF7 | Function assay | 24 hrs | Increase in p53 expression in human MCF7 cells nuclei after 24 hrs by DAPI staining based immunofluorescence microscopy | 27010502 | ||
| MCF7 | Function assay | 24 hrs | Upregulation of p21 in human MCF7 cells after 24 hrs by Western blot analysis | 27010502 | ||
| HCT116 | Function assay | 50 uM | 24 hrs | Inhibition of p53-MDM2 (unknown origin) interaction expressed in p53-deficient human HCT116 cells at 50 uM after 24 hrs by BiFC-based FACS flow cytometric analysis | 24268795 | |
| U2OS | Function assay | 2.5 uM | 12 hrs | Stabilization of p53 in human U2OS cells assessed as intracellular p53 level at 2.5 uM after 12 hrs by Western blotting | 26288684 | |
| HCT116 | Function assay | 10 uM | 20 hrs | Inhibition of V1-p53/MDM2-V2 (unknown origin) interaction expressed in human HCT116 p53-/- cells at 10 uM after 20 hrs by biomolecular fluorescence complementation-based flow cytometric analysis | 28800455 | |
| IMR32 | Function assay | 24 hrs | Increase in p53 expression in human IMR32 cells nuclei after 24 hrs by DAPI staining based immunofluorescence microscopy | 27010502 | ||
| MCF7 | Function assay | 10 uM | 16 hrs | Inhibition of MDM2-p53 interaction in human MCF7 cells assessed as reversal of MDM2-dependent inhibition of p53-induced transcriptional activity at 10 uM after 16 hrs by dual-luciferase reporter gene assay | 23540934 | |
| MCF7 | Apoptosis assay | 3 uM | 24 to 72 hrs | Induction of apoptosis in human MCF7 cells assessed as reduction in Bcl-xL expression level at 3 uM after 24 to 72 hrs by Western blotting analysis | 23802716 | |
| MCF7 | Apoptosis assay | 3 uM | 24 to 72 hrs | Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 3 uM after 24 to 72 hrs by annexin V-FITC/propidium iodide staining based FACS flow cytometry (Rvb = 4 %) | 23802716 | |
| MCF7 | Apoptosis assay | 3 uM | 24 to 72 hrs | Induction of apoptosis in human MCF7 cells assessed as increase in p21 expression level at 3 uM after 24 to 72 hrs by Western blotting analysis | 23802716 | |
| MCF7 | Apoptosis assay | 3 uM | 24 to 72 hrs | Induction of apoptosis in human MCF7 cells assessed as increase in Bcl-xS expression level at 3 uM after 24 to 72 hrs by Western blotting analysis | 23802716 | |
| MCF7 | Apoptosis assay | 50 nM | 24 to 72 hrs | Induction of apoptosis in human MCF7 cells assessed as accumulation of caspase-3 cleavage product at 50 nM after 24 to 72 hrs by Western blotting analysis | 23802716 | |
| MCF7 | Cell cycle assay | 3 uM | 24 to 72 hrs | Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 3 uM after 24 to 72 hrs by propidium iodide staining-based FACS analysis | 23802716 | |
| Clicca per visualizzare più dati sperimentali sulle linee cellulari | ||||||
| Peso molecolare | 581.49 | Formula | C30H30Cl2N4O4 |
Conservazione (Dalla data di ricezione) | |
|---|---|---|---|---|---|
| N. CAS | 675576-98-4 | -- | Conservazione delle soluzioni stock |
|
|
| Sinonimi | (-)-Nutlin-3 | Smiles | CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl | ||
|
In vitro |
DMSO
: 100 mg/mL
(171.97 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Passo 1: Inserire le informazioni di seguito (Consigliato: Un animale aggiuntivo per tenere conto della perdita durante l'esperimento)
Passo 2: Inserire la formulazione in vivo (Questo è solo il calcolatore, non la formulazione. Contattateci prima se non c'è una formulazione in vivo nella sezione Solubilità.)
Risultati del calcolo:
Concentrazione di lavoro: mg/ml;
Metodo per preparare il liquido master di DMSO: mg farmaco predissolto in μL DMSO ( Concentrazione del liquido master mg/mL, Vi preghiamo di contattarci prima se la concentrazione supera la solubilità del DMSO del lotto del farmaco. )
Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungereμL PEG300, mescolare e chiarire, quindi aggiungereμL Tween 80, mescolare e chiarire, quindi aggiungere μL ddH2O, mescolare e chiarire.
Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungere μL Olio di mais, mescolare e chiarire.
Nota: 1. Si prega di assicurarsi che il liquido sia limpido prima di aggiungere il solvente successivo.
2. Assicurarsi di aggiungere il/i solvente/i in ordine. È necessario assicurarsi che la soluzione ottenuta, nell'aggiunta precedente, sia una soluzione limpida prima di procedere all'aggiunta del solvente successivo. Metodi fisici come il vortex, gli ultrasuoni o il bagno d'acqua calda possono essere utilizzati per facilitare la dissoluzione.
| Caratteristiche |
Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
|
|---|---|
| Targets/IC50/Ki |
p53-MDM2 interaction
(Cell-free assay) 90 nM
|
| In vitro |
Nutlin-3a sposta p53 dalla tasca di legame di MDM2 e, di conseguenza, rilascia p53 dall'inibizione e dalla degradazione proteasomica, portando all'induzione dei suoi bersagli a valle, all'arresto del ciclo cellulare e all'apoptosis. Sette giorni di incubazione con 10 μM di questo composto hanno portato a >90% di inibizione della crescita delle cellule NIH3T3. Questo composto stabilizza e attiva p53 e induce l'espressione di p21 in modo dose-dipendente. Depleisce efficacemente il compartimento della fase S al 0,2-2% e aumenta i compartimenti delle fasi G1 e G2/M. Questa sostanza chimica induce l'apoptosis in circa il 60% delle cellule SJSA-1 e MHM
dopo 40 h, percentuale che è ulteriormente aumentata dopo 60 h (85% e 65%, rispettivamente) .
|
| Saggio chinasico |
Studi Biacore
|
|
I saggi di competizione sono eseguiti su un Biacore S51. Un chip sensore Series S CM5 è derivatizzato per l'immobilizzazione di un anticorpo PentaHis per la cattura del p53 marcato con His. Il livello di cattura è di circa 200 unità di risposta (1 unità di risposta corrisponde a 1 pg di proteina per mm2). La concentrazione della proteina MDM2 è mantenuta costante a 300 nM. I composti di prova sono disciolti in DMSO a 10 mM e ulteriormente diluiti per creare una serie di concentrazioni di inibitore in ogni campione di prova MDM2. I saggi vengono eseguiti a 25 °C in tampone di corsa (10 mM Hepes, 0,15 M NaCl, 2% DMSO). Il legame MDM2-p53 in presenza di questo composto è calcolato come percentuale del legame in assenza di questo composto e l'IC50 è calcolato utilizzando Microsoft Excel.
|
|
| In vivo |
Nutlin-3a sopprime la crescita del trapianto in modo dose-dipendente, con la dose più alta (200 mg/kg) che mostra una sostanziale riduzione del tumore . Questo composto è un attivatore selettivo della via p53 in vivo e altamente efficace contro i tumori di osteosarcoma SJSA-1. I tumori con p53 wild-type e amplificazione del gene MDM2 risponderanno meglio alla terapia con questa sostanza chimica.
|
Riferimenti |
|
| Metodi | Biomarcatori | Immagini | PMID |
|---|---|---|---|
| Western blot | p53 / MDM2 / p21 / Bax / Bak / Noxa / cleaved caspase / pro-caspase BMI-1 p53-Ser15 / p53-Ser37 / p53-Lys382 / MDM2 / CDC2 / PLK1 / HSC70 |
|
16014563 |
| Immunofluorescence | p-p21 / β-actin P53 Ac-p300 |
|
31083332 |
| Growth inhibition assay | Cell viability |
|
26248031 |
Domanda 1:
What is the difference between S1061 (Nutlin-3) and it?
Risposta:
S1061 is a racemic mixture of Nutlin3a and Nutlin3b. Its active enantiomer is s8059.